Abstract
RNA interference (RNAi) is a collection of small RNA-directed mechanisms that result in sequence-specific inhibition of gene expression. RNAi delivery has demonstrated promising efficacy in the treatment of genetic disorders in cancer. Although viral vectors are currently the most efficient systems for gene therapy, potent immunogenicity, mutagenesis, and the biohazards of viral vectors remain their major risks. Various non-viral delivery vectors have been developed to provide a safer approach for gene delivery, including polymers, peptides, liposomes, and nanoparticles. However, some concerns and challenges of these non-viral gene delivery approaches remain to be overcome. In this review, we summarize the recent progress in the development of non-viral systems delivering RNAi and the currently available preclinical and clinical data, and discuss the challenges and future directions in cancer therapy.
Keywords: Cancer gene therapy, liposomes, microRNA, non-viral delivery, nuclear localization signal, polymers, RNA interference, siRNA.
Current Gene Therapy
Title:Non-Viral Delivery of RNA Interference Targeting Cancer Cells in Cancer Gene Therapy
Volume: 12 Issue: 4
Author(s): Pin-I Huang, Wen-Liang Lo, Jong-Yuh Cherng, Yueh Chien, Guang-Yuh Chiou and Shih-Hwa Chiou
Affiliation:
Keywords: Cancer gene therapy, liposomes, microRNA, non-viral delivery, nuclear localization signal, polymers, RNA interference, siRNA.
Abstract: RNA interference (RNAi) is a collection of small RNA-directed mechanisms that result in sequence-specific inhibition of gene expression. RNAi delivery has demonstrated promising efficacy in the treatment of genetic disorders in cancer. Although viral vectors are currently the most efficient systems for gene therapy, potent immunogenicity, mutagenesis, and the biohazards of viral vectors remain their major risks. Various non-viral delivery vectors have been developed to provide a safer approach for gene delivery, including polymers, peptides, liposomes, and nanoparticles. However, some concerns and challenges of these non-viral gene delivery approaches remain to be overcome. In this review, we summarize the recent progress in the development of non-viral systems delivering RNAi and the currently available preclinical and clinical data, and discuss the challenges and future directions in cancer therapy.
Export Options
About this article
Cite this article as:
Huang Pin-I, Lo Wen-Liang, Cherng Jong-Yuh, Chien Yueh, Chiou Guang-Yuh and Chiou Shih-Hwa, Non-Viral Delivery of RNA Interference Targeting Cancer Cells in Cancer Gene Therapy, Current Gene Therapy 2012; 12 (4) . https://dx.doi.org/10.2174/156652312802083576
DOI https://dx.doi.org/10.2174/156652312802083576 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metabotropic Glutamate Receptors in Central Nervous System Diseases
Current Drug Targets The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Nanotechnology and Radiopharmaceuticals: Diagnostic and Therapeutic Approaches
Current Drug Delivery Design, Synthesis, Computational and Biological Evaluation of Two New Series of 1, 3- and 1,6-dihydroxy Xanthone Derivatives as Selective COX-2 Inhibitors
Letters in Drug Design & Discovery Voltage-Gated Sodium Channel Blockers as Immunomodulators
Recent Patents on CNS Drug Discovery (Discontinued) Use of Bimetallic Nanoparticles in the Synthesis of Heterocyclic Molecules
Current Organic Chemistry Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions
Current Drug Targets Potential Use of Polymeric Nanoparticles for Drug Delivery Across the Blood-Brain Barrier
Current Medicinal Chemistry Semaphorins at the Interface of Development and Cancer
Current Drug Targets MicroRNAs in Cancer Therapy: From Bench to Bedside
Current Cancer Therapy Reviews Anticancer Drug Discovery from the Marine Environment
Recent Patents on Anti-Cancer Drug Discovery Dietary Phytochemicals in Chemoprevention of Cancer: An Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) EGF-R Small Inhibitors and Anti-EGF-R Antibodies: Advantages and Limits of a New Avenue in Anticancer Therapy
Recent Patents on Anti-Cancer Drug Discovery The Blood-Brain/Tumor Barriers: Challenges and Chances for Malignant Gliomas Targeted Drug Delivery
Current Pharmaceutical Biotechnology Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal 2-(ω-Carboxyethyl)pyrrole Antibody as a New Inhibitor of Tumor Angiogenesis and Growth
Anti-Cancer Agents in Medicinal Chemistry Bismuth-213 and Actinium-225 – Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting Radioisotopes
Current Radiopharmaceuticals Using Free and Open-Source Bioconductor Packages to Analyze Array Comparative Genomics Hybridization (aCGH) Data
Current Genomics Connexins as Precocious Markers and Molecular Targets for Chemical and Pharmacological Agents in Carcinogenesis
Current Medicinal Chemistry Peptide Prodrugs for the Treatment of CNS Disorders: A Perspective for New Drugs
Current Medicinal Chemistry